The Changes in the Endothelial Function and Haemostatic and Inflammatory Parameters in Subclinical and Overt Hyperthyroidism
Table 3
Selected markers of inflammation and endothelial dysfunction in the patients with Graves disease (GD), toxic nodular goitre (TNG), and in the control group.
GD () median (C25–C75)
TNG () median (C25–C75)
Control group () median (C25–C75)
value
IL-6 (ng/mL)
2.3 (1.3–3.9)
1.5 (1.0–3.0)
1.2 (0.7–1.8)
,
IL-12 (pg/mL)
3.3 (1.6–6.4)
1.9 (0.5–4.9)
0.5 (0.5–1.4)
,
IL-18 (pg/mL)
287.2 (180.5–368.9)
217.9 (164.5–322.4)
232.8 (181.1–257.8)
PAI-1 (ng/mL)
58.5 (42.4–92.5)
56.4 (28.0–88.1)
31.5 (18.2–47.0)
,
vWF (ng/mL)
133.3 (118.7–141.8)
118.0 (98.7–135.9)
94.2 (73.0–116.3)
,
E-selectin (ng/mL)
53.0 (42.0–80.0)
50.0 (34.0–66.0)
58.0 (40.0–68.0)
NS
sICAM-1 (ng/mL)
341.0 (300.0–418.0)
320.0 (258.0–394.0)
314.0 (278.0–404.0)
NS
sVCAM-1 (ng/mL)
1210.0 (950.0–1666.0)
1106.1 (840.0–1385.0)
792.0 (607.0–1010.0)
,
CRP (ng/mL)
3.4 (2.9–4.7)
3.8 (2.9–4.9)
3.2 (2.7–4.3)
NS
Fibrinogen (ng/mL)
303.5 (212.0–368.0)
257.0 (181.0–358.0)
244.0 (185.0–325.0)
NS
Data are shown as medians with interquartile ranges. Differences between groups were compared by the Kruskal-Wallis test.
*Differences between GD and control group, **differences between TNG and control group, NS: not significant.
